In this context, TAT–GILZ, acting by a different mechanism than GCs and successfully described in preclinical studies as a pharmacological tool for the treatment of inflammation or autoimmune diseases,93–97 paves the way for the investigation of a new therapeutic strategy. Here, TSC22D3 is linked to autoimmune disease.